http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c71637cba40fbc8d17679e87de2d741
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Brown |
| name | Jennifer R. Brown Jennifer R Brown |
| given-name | Jennifer R. Jennifer R |
| organization-name | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and CLL Center, Dana Farber Cancer Institute, Boston, MA, USA Jennifer R. Brown, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Neil E. Kay, Mayo Clinic, Rochester, MN From the Department of Medical Oncology, Dana–Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska–Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the... From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and First Health of the Carolinas Cancer Center, Pinehurst (C.K.) — both in North Carolina; the... Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA;; Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, Massachusetts. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 3Harvard Medical School, Boston, Massachusetts.; 16Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA; Harvard Medical School Boston MA USA Harvard Medical School, Boston, MA;; CLL Center, DFCI, Boston, MA 1Dana-Farber Cancer Institute, Boston, Massachusetts. From the Department of Medical Oncology, Department of Biostatistical Science, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women’s Hospital; Department of Medicine, Massachusetts General Hospital; and Department of Medicine, Harvard Medical School, Boston, MA; James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY From the Departments of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston; and the Department of Medicine, Cambridge Hospital, Cambridge, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA Dana-Farber Cancer Institute, Boston, MA [email protected]. Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, Boston, MA 1Division of Neuroscience, Children’s Hospital; 2Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115 Dana-Farber Cancer Institute, Boston, Massachusetts, United States Authors' Affiliation: Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts The Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA;; Dana-Farber Cancer Institute, Boston, MA; Department of Medicine Harvard Medical School Boston MA USA; Department of Medical Oncology Dana Farber Cancer Institute Boston MA USA Authors' Affiliations: 1Departments of Medicine and 2Pathology, Dartmouth-Hitchcock Medical Center, Lebanon; 3Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and 4Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts, USA Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA; Chemical and Biological Engineering Montana State University Bozeman Montana USA Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA Authors' Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts Department of Medical Oncology, Dana−Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02115, United States Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Brookline,MA Department of Medicine, Division of Hematological Malignancies Dana‐Farber Cancer Institute Boston Massachusetts Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; Qingshan Yang, Prexy Modi, Anil Korkut, and Varsha Gandhi, The University of Texas MD Anderson Cancer Center, Houston, TX; Stacey M. Fernandes, John Hanna, and Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, MA Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Medical Oncology and 3Department of Biostatistics, Dana-Farber Cancer Institute; 4Department of Pathology, Massachusetts General Hospital; and 5Medicine, Harvard Medical School, Boston, MA; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Medical Oncology and 3Department of Biostatistics, Dana-Farber Cancer Institute; 4Department of Pathology, Massachusetts General Hospital; and 5Medicine, Harvard Medical School, Boston, MA Dana-Farber Cancer Institute; Harvard Medical School Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, United States Departments of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA;; CLL Research Consortium, Moores Cancer Center, UC San Diego Health, La Jolla, CA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA Dana Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA DANA-FARBER CANCER INSTITUTE Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA. From the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Boston, MA; Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA; Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX. Authors' Affiliations: 1Department of Medicine, Brigham and Women's Hospital; 2Dana-Farber Cancer Institute, Boston, Massachusetts; 3Laboratory for Translational Research, Harvard Medical School, Cambridge, Massachusetts; 4Sino Recombi Pharma, Suzhou, China; and 5Department of General Surgery, Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;; Department of Medicine, Harvard Medical School, Boston, MA, USA 1Department of Medical Oncology, Dana-Farber Cancer Institute,; 2Harvard Medical School, Boston, Massachusetts. Laboratory of Molecular Psychiatry, Departments of Psychiatry and Pharmacology, Yale University School of Medicine and Connecticut Mental Health Center, 34 Park Street, New Haven, CT 06508; and Division of Neuroscience, Children’s Hospital, Ender’s Building and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115 Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Harvard Medical School, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Cancer Genome Discovery, 4Center for Cancer Computational Biology, Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center; 6Department of Pathology, Brigham and Women's Hospital; 7Department of Medicine, Harvard Medical School, Boston; 8Broad Institute of Harvard and Massachusetts Institute of Technology (MIT); 9Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; Cambridge, Massachusetts; and 10Department of Plant Systems Biology, VIB, Department of Biotechnology and Genetics, Ghent University, Gent, Belgium; Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Cancer Genome Discovery, 4Center for Cancer Computational Biology, Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center; 6Department of Pathology, Brigham and Women's Hospital; 7Department of Medicine, Harvard Medical School, Boston; 8Broad Institute of Harvard and Massachusetts Institute of Technology (MIT); 9Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology; Cambridge, Massachusetts; and 10Department of Plant Systems Biology, VIB, Department of Biotechnology and Genetics, Ghent University, Gent, Belgium Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Hematologic Malignancies, Dana-Farber/Partners Cancer Care, Boston, MA, USA; Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA United States of America Authors' Affiliations: 1Center for Molecular Medicine, the First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China; 2Laboratory for Translational Research, Harvard Medical School, Cambridge; 3Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5Department of Hematology, Shanghai First People's Hospital, Shanghai, China; Authors' Affiliations: 1Center for Molecular Medicine, the First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China; 2Laboratory for Translational Research, Harvard Medical School, Cambridge; 3Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5Department of Hematology, Shanghai First People's Hospital, Shanghai, China Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School Boston, MA, USA From the Departments of Leukemia, Experimental Therapeutics, Phase I Program, and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX; University of California San Diego Moore's Cancer Center, San Diego, CA; and Dana-Farber Cancer Institute, Boston, MA Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA;; Department of Medical Oncology, Dana-Farber Cancer Institute, and; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Harvard Medical School, Boston, MA CLL Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA CLL Center, Dana-Farber Cancer Institute, Boston, MA Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C.... Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; CLL Center, Dana‐Farber Cancer Institute Boston Massachusetts Department of Biology University of South Dakota Vermillion South Dakota USA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA Dana-Farber Cancer Institute, Boston, MA 02215, USA Dana Farber Cancer Institute, Boston, MA Department of Medicine, Brigham and Women’s Hospital, Boston, MA;; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Department of Medical Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, Massachusetts 2Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Author affiliations appear at the end of this article. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 2Harvard Medical School, Boston, Massachusetts. Chronic Lymphocytic Leukemia Center Division of Medical Oncology Dana‐Farber Cancer Institute and Harvard Medical School Boston Massachusetts USA Mary Beth Landrum, Nancy L. Keating, Elizabeth B. Lamont, and Barbara J. McNeil, Harvard Medical School; Nancy L. Keating and Barbara J. McNeil, Brigham and Women's Hospital; Elizabeth B. Lamont, Massachusetts General Hospital Cancer Center; Lawrence Shulman, Jennifer R. Brown, and Michael Rabin, Dana-Farber Cancer Institute, Boston; Samuel R. Bozeman, Abt Associates, Cambridge, MA; Steven H. Krasnow, Washington, DC Veterans Affairs Medical Center, Washington, DC; and Craig C. Earle, Sunnybrook Health... 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 4Harvard Medical School, Boston, Massachusetts.; 11Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Authors' Affiliations: 1Center for Evaluation Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Departments of 2Imaging and 3Medical Oncology, Dana–Farber Cancer Institute; 4Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and 5Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Harvard Medical School and CLL Center, Dana-Farber Cancer Institute, Boston, MA Department of Medical Oncology Dana Farber Cancer Institute Harvard Medical School Boston MA USA Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. [email protected] Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA 02215 USA Dana-Farber Cancer Institute, Boston, MA, USA Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA; Departments of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA Departments of Chemical and Biological Engineering, Mechanical and Industrial Engineering, and Chemistry and Center for Biofilm Engineering, Montana State University, Bozeman, MT, International Tomography Center, Novosibirsk State University, and Boreskov Institute of Catalysis, SB RAS, Novosibirsk, Russia Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 5Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Danelle F. James, Januario E. Castro, Andrew Greaves, Laura Z. Rassenti, Thomas J. Kipps, Moores Cancer Center, University of California San Diego, La Jolla, CA; Lillian Werner, Jennifer R. Brown, Donna Neuberg, Dana-Farber Cancer Institute, Boston, MA; William G. Wierda, MD Anderson Cancer Center, The University of Texas, Houston, TX; Jacqueline C. Barrientos, Kanti R. Rai, North Shore–Long Island Jewish Health System, New Hyde Park, NY; Amy J. Johnson, The Ohio State University, Columbus, OH. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA;; CLL Research Consortium; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Medical Oncology Dana‐Farber Cancer Institute Boston MA USA Harvard Medical School Boston Massachusetts; Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA |
Incoming Links
Showing number of triples: 1 to 379 of 379.